| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10000115 | HBV | ENSG00000036828.17 | protein_coding | CASR | Yes | Yes | 846 | P41180 |
| TVIS10000116 | HBV | ENSG00000036828.17 | protein_coding | CASR | Yes | Yes | 846 | P41180 |
| TVIS10014155 | HBV | ENSG00000036828.17 | protein_coding | CASR | Yes | Yes | 846 | P41180 |
| TVIS20036567 | HPV | ENSG00000036828.17 | protein_coding | CASR | Yes | Yes | 846 | P41180 |
| TVIS20042433 | HPV | ENSG00000036828.17 | protein_coding | CASR | Yes | Yes | 846 | P41180 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CASR |
|---|---|
| DrugBank ID | DB01012 |
| Drug Name | Cinacalcet |
| Target ID | BE0000509 |
| UniProt ID | P41180 |
| Regulation Type | agonist |
| PubMed IDs | 15794735; 15864123; 15884662; 16030053; 16109140; 19461861; 19261825; 19181759; 19056615; 11752352 |
| Citations | de Francisco AL: Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. Expert Opin Pharmacother. 2005 Mar;6(3):441-52.@@Rothe HM, Shapiro WB, Sun WY, Chou SY: Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet Genomics. 2005 Jan;15(1):29-34.@@Tasic V: Management of renal osteodystrophy in children. Turk J Pediatr. 2005;47 Suppl:13-8.@@Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct;20(10):2186-93. Epub 2005 Jul 19.@@Cunningham J: Management of secondary hyperparathyroidism. Ther Apher Dial. 2005 Aug;9 Suppl 1:S35-40.@@Eriguchi R, Umakoshi J, Tominaga Y, Sato Y: Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl. NDT Plus. 2008 Aug;1(4):218-220. Epub 2008 May 25.@@Belozeroff V, Goodman WG, Ren L, Kalantar-Zadeh K: Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009 Mar;4(3):673-9. doi: 10.2215/CJN.03790808. Epub 2009 Mar 4.@@Meola M, Petrucci I, Barsotti G: Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2009 Mar;24(3):982-9. doi: 10.1093/ndt/gfn654. Epub 2009 Jan 30.@@Drueke TB, Ritz E: Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives. Clin J Am Soc Nephrol. 2009 Jan;4(1):234-41. doi: 10.2215/CJN.04520908. Epub 2008 Dec 3.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved |
| Direct Classification | Naphthalenes |
| SMILES | C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C1=CC=CC2=CC=CC=C12 |
| Pathways | |
| PharmGKB | PA164776671 |
| ChEMBL | CHEMBL1201284 |
